81 Recruiting Studies Using Abiraterone
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Abiraterone
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
📍 Urology Centers Of Alabama — Homewood, Alabama
Castration-Resistant Prostatic Cancer
View Study & Checklist ➔Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
📍 Research Site — Tucson, Arizona
Hormone-Sensitive Prostate Cancer
View Study & Checklist ➔A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
📍 St. Joseph's Hospital and Medical Center — Phoenix, Arizona
Prostate Cancer
View Study & Checklist ➔Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
📍 Yale Cancer Center — New Haven, Connecticut
Stage II Prostate Adenocarcinoma
View Study & Checklist ➔Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer
📍 OHSU Knight Cancer Institute — Portland, Oregon
Castration-Sensitive Prostate Carcinoma
View Study & Checklist ➔Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
📍 H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
Prostate Cancer
View Study & Checklist ➔A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
📍 Urological Associates of Southern Arizona, P.C. — Tucson, Arizona
Prostatic Neoplasms, Castration-Resistant
View Study & Checklist ➔A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
📍 Clinical Research Facility — Los Angeles, California
Prostatic Neoplasms
View Study & Checklist ➔Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
📍 Arizona Institute of Urology (AIU) - Tucson — Tucson, Arizona
Metastatic Castration-Resistant Prostate Cancer
View Study & Checklist ➔Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
📍 M D Anderson Cancer Center — Houston, Texas
Prostate Adenocarcinoma
View Study & Checklist ➔Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
📍 Research Site — Detroit, Michigan
Metastatic Prostate Cancer
View Study & Checklist ➔A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
📍 Urology Centers Of Alabama — Homewood, Alabama
Metastatic Castration-sensitive Prostate Cancer
View Study & Checklist ➔Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer
📍 H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
Prostate Cancer
View Study & Checklist ➔A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
📍 Indiana University — Bloomington, Indiana
Urothelial Carcinoma
View Study & Checklist ➔An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
📍 Clinical Research Facility — Phoenix, Arizona
Prostatic Neoplasms
View Study & Checklist ➔Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
📍 University of California Los Angeles — Los Angeles, California
Prostate Cancer Metastatic Castration-Resistant
View Study & Checklist ➔Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
📍 Moffitt Cancer Center — Tampa, Florida
Prostate Cancer
View Study & Checklist ➔An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
📍 University of California San Diego - Moores Cancer Center — La Jolla, California
Metastatic Hormone-sensitive Prostate Cancer
View Study & Checklist ➔177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer
📍 Arizona Institute of Urology, PPLC — Tucson, Arizona
Metastasis From Malignant Tumor of Prostate
View Study & Checklist ➔Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
📍 University of California Davis Comprehensive Cancer Center — Sacramento, California
Metastatic Prostate Carcinoma
View Study & Checklist ➔A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
📍 Arizona Oncology Associates, P.C. - HOPE — Prescott, Arizona
Prostatic Neoplasms
View Study & Checklist ➔Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
📍 UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
Metastatic Prostate Adenocarcinoma
View Study & Checklist ➔Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Metastatic Prostate Cancer
View Study & Checklist ➔Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
📍 Research Site — Chandler, Arizona
Metastatic Castration-Sensitive Prostate Cancer
View Study & Checklist ➔Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
📍 Exelixis Clinical Site #4 — Tucson, Arizona
Metastatic Prostate Cancer
View Study & Checklist ➔M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
📍 NEXT Oncology - PARENT — New York, New York
Advanced Solid Tumor
View Study & Checklist ➔A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
📍 START Mountain Region — West Valley City, Utah
Prostatic Neoplasms
View Study & Checklist ➔A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
📍 University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
Prostate Cancer
View Study & Checklist ➔ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer
📍 UC San Diego Moores Cancer Center — La Jolla, California
Metastatic Prostate Cancer
View Study & Checklist ➔A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
📍 Site US10052 — Anchorage, Alaska
Prostate Cancer
View Study & Checklist ➔A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
📍 City of Hope National Medical — Duarte, California
Prostate Cancer Metastatic
View Study & Checklist ➔Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
📍 Research Site — Birmingham, Alabama
Metastatic Castration-resistant Prostate Cancer
View Study & Checklist ➔Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
📍 M D Anderson Cancer Center — Houston, Texas
Castration Levels of Testosterone
View Study & Checklist ➔Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
📍 University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
Prostate Cancer
View Study & Checklist ➔Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
📍 University of Chicago — Chicago, Illinois
Prostate Cancer
View Study & Checklist ➔Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
📍 City of Hope Comprehensive Cancer Center — Los Angeles, California
Castration-Resistant Prostatic Cancer
View Study & Checklist ➔Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms
📍 Medicine Invention Design, Inc. - IORG0007849 - NPI-1023387701 — Rockville, Maryland
Prostate Cancer
View Study & Checklist ➔Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
📍 Fairbanks Memorial Hospital — Fairbanks, Alaska
Castration Levels of Testosterone
View Study & Checklist ➔Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
📍 University of Alabama at Birmingham — Birmingham, Alabama
Metastatic Castration-resistant Prostate Cancer
View Study & Checklist ➔Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
📍 M D Anderson Cancer Center — Houston, Texas
Metastatic Prostate Carcinoma
View Study & Checklist ➔Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial
📍 Mayo Clinic in Rochester — Rochester, Minnesota
Recurrent Prostate Adenocarcinoma
View Study & Checklist ➔Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
📍 Research Site — Ottawa, Ontario
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
View Study & Checklist ➔Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
📍 City of Hope National Medical Center — Duarte, California
Prostate Cancer
View Study & Checklist ➔Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
📍 University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040) — Orange, California
Prostate Cancer Metastatic
View Study & Checklist ➔Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
📍 University of Pittsburgh Cancer Institute (UPCI) — Pittsburgh, Pennsylvania
Prostate Adenocarcinoma
View Study & Checklist ➔Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
📍 VA Greater Los Angeles Healthcare System — Los Angeles, California
Metastatic Cancer
View Study & Checklist ➔Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
📍 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
Prostate Cancer (Adenocarcinoma)
View Study & Checklist ➔Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
📍 City of Hope Medical Center — Duarte, California
Castration-Sensitive Prostate Carcinoma
View Study & Checklist ➔A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
📍 Precision Point Specialty LLC PPS Analytics, a Specialty Networks LLC Company — Cleveland, Ohio
Prostatic Neoplasms
View Study & Checklist ➔A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
📍 Florida Cancer Specialists — Sarasota, Florida
Metastatic Castration-resistant Prostate Neoplasms
View Study & Checklist ➔A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
📍 Research Site 111 — Tucson, Arizona
Advanced Solid Tumors
View Study & Checklist ➔A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
📍 UCLA Hematology & Oncology ( Site 0003) — Los Angeles, California
Castration-Resistant Prostatic Cancer
View Study & Checklist ➔A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
📍 City of Hope Cancer Center Phoenix — Goodyear, Arizona
Metastatic Castration-resistant Prostate Cancer
View Study & Checklist ➔Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
📍 University of California Davis Comprehensive Cancer Center — Sacramento, California
Advanced Prostate Adenocarcinoma
View Study & Checklist ➔SNV1521 in Participants With Advanced Solid Tumors
📍 Smilow Cancer Hospital at Yale New Haven — New Haven, Connecticut
Advanced Solid Tumor
View Study & Checklist ➔Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
📍 University of California Davis — Sacramento, California
Prostate Cancer
View Study & Checklist ➔AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
📍 Research Site — Dothan, Alabama
Metastatic Castration-resistant Prostate Cancer
View Study & Checklist ➔Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Castration-Resistant Prostate Carcinoma
View Study & Checklist ➔Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer
📍 Mayo Clinic in Arizona — Scottsdale, Arizona
Oligometastatic Prostate Carcinoma
View Study & Checklist ➔TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
📍 Univ of Alabama at Birmingham — Birmingham, Alabama
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
View Study & Checklist ➔Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)
📍 Princess Margaret Cancer Center — Toronto, Ontario
Metastatic Prostate Cancer
View Study & Checklist ➔A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
📍 Research Site — Phoenix, Arizona
Prostate Cancer
View Study & Checklist ➔A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
📍 VA Greater LA Healthcare System — Los Angeles, California
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
View Study & Checklist ➔Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
📍 University of California San Francisco — San Francisco, California
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
View Study & Checklist ➔The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
📍 Chao Family Comprehensive Cancer Centre — Orange, California
Metastatic Castration-resistant Prostate Cancer
View Study & Checklist ➔A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
📍 VA Greater Los Angeles Healthcare System, West Los Angeles, CA — West Los Angeles, California
High-Risk Prostate Cancer
View Study & Checklist ➔A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
📍 The University of Arizona Cancer Center - North Campus ( Site 0073) — Tucson, Arizona
Metastatic Castration-resistant Prostate Cancer (mCRPC)
View Study & Checklist ➔Study of ORIC-944 in Patients With Metastatic Prostate Cancer
📍 Rocky Mountain Cancer Center — Colorado Springs, Colorado
Metastatic Prostate Cancer
View Study & Checklist ➔A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
📍 Clearview Cancer Institute — Huntsville, Alabama
Prostate Cancer
View Study & Checklist ➔A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
📍 Mary Crowley Cancer Research — Dallas, Texas
Metastatic Castration-resistant Prostate Cancer (mCRPC)
View Study & Checklist ➔Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
📍 M D Anderson Cancer Center — Houston, Texas
Prostate Carcinoma
View Study & Checklist ➔A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
📍 VA West Los Angeles Medical Center - (CRS) - NAVREF - PPDS — Los Angeles, California
Metastatic Castration-Resistant Prostate Cancer
View Study & Checklist ➔Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer
📍 Ben Taub General Hospital — Houston, Texas
Prostate Cancer Metastatic
View Study & Checklist ➔Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Prostate Cancer (Adenocarcinoma)
View Study & Checklist ➔Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
📍 University of Nebraska Medical Center — Omaha, Nebraska
Prostate Cancer
View Study & Checklist ➔A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
📍 Central Alabama Research — Birmingham, Alabama
Metastatic Castration-resistant Prostate Cancer
View Study & Checklist ➔REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
📍 Emory Proton Therapy Center — Atlanta, Georgia
Recurrent Prostate Carcinoma
View Study & Checklist ➔Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
Castration Levels of Testosterone
View Study & Checklist ➔Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
📍 Mayo Clinic in Arizona — Phoenix, Arizona
Recurrent Castration-Sensitive Prostate Carcinoma
View Study & Checklist ➔Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone
📍 University of California, San Francisco — San Francisco, California
High Risk Prostate Carcinoma
View Study & Checklist ➔A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
📍 Yale University (Data Collection Only) — New Haven, Connecticut
Prostate Cancer
View Study & Checklist ➔